Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Revenue of $3.14M

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.

Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters